CaDAnCe-101
Phase 1/2 Recruiting
614 enrolled
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
Phase 1/2 Recruiting
439 enrolled
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Phase 1/2 Recruiting
155 enrolled
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Phase 1/2 Recruiting
126 enrolled
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
Phase 1/2 Recruiting
940 enrolled 1 FDA
SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas
Phase 1/2 Recruiting
48 enrolled
A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma
Phase 1/2 Recruiting
37 enrolled
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Phase 1/2 Recruiting
147 enrolled
Study of LYL314 in Aggressive Large B-Cell Lymphoma
Phase 1/2 Recruiting
270 enrolled
Lumi-NHL
Phase 1/2 Recruiting
91 enrolled
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
Phase 1/2 Recruiting
100 enrolled
SELECT-CAR-NK
Phase 1/2 Recruiting
85 enrolled
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Phase 1/2 Recruiting
32 enrolled
ACIT001/EXC002
Phase 1/2 Recruiting
63 enrolled
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Phase 1/2 Recruiting
250 enrolled
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
Phase 1/2 Recruiting
120 enrolled
Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)
Phase 1/2 Recruiting
12 enrolled
A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies
Phase 1/2 Recruiting
40 enrolled
A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 1/2 Recruiting
40 enrolled
CLIC-01
Phase 1/2 Recruiting
60 enrolled
STARLIGHT-1
Phase 1/2 Recruiting
21 enrolled
BAH241
Phase 1/2 Recruiting
75 enrolled
A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies
Phase 1/2 Recruiting
84 enrolled
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Phase 1/2 Recruiting
152 enrolled
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Phase 1/2 Recruiting
128 enrolled
TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL
Phase 1/2 Recruiting
30 enrolled
TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma
Phase 1/2 Recruiting
30 enrolled
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Phase 1/2 Recruiting
275 enrolled
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Phase 1/2 Recruiting
146 enrolled
Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma
Phase 1/2 Recruiting
184 enrolled
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
Phase 1/2 Recruiting
100 enrolled
PTCy and ATG for MSD and MUD Transplants
Phase 1/2 Recruiting
50 enrolled
CARTHEDRALL
Phase 1/2 Recruiting
81 enrolled
A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL
Phase 1/2 Recruiting
132 enrolled
GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies
Phase 1/2 Recruiting
50 enrolled
TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
Phase 1/2 Recruiting
30 enrolled
Chidamide Bridging for CAR-T Therapy
Phase 1/2 Recruiting
120 enrolled
APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 1/2 Recruiting
51 enrolled
Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 1/2 Recruiting
100 enrolled
Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor
Phase 1/2 Recruiting
100 enrolled
CART30
Phase 1/2 Recruiting
30 enrolled